S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
Log in

NASDAQ:NTRA - Natera Stock Price, Forecast & News

$37.13
+1.12 (+3.11 %)
(As of 02/19/2020 04:00 PM ET)
Today's Range
$36.04
Now: $37.13
$37.46
50-Day Range
$32.84
MA: $35.42
$37.64
52-Week Range
$14.71
Now: $37.13
$40.92
Volume405,148 shs
Average Volume600,147 shs
Market Capitalization$2.88 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.35
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTRA
CUSIPN/A
Phone650-249-9090

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$257.65 million
Book Value$0.52 per share

Profitability

Net Income$-128,150,000.00

Miscellaneous

Employees975
Market Cap$2.88 billion
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable

Receive NTRA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.


Natera (NASDAQ:NTRA) Frequently Asked Questions

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

How were Natera's earnings last quarter?

Natera Inc (NASDAQ:NTRA) issued its quarterly earnings data on Wednesday, November, 6th. The medical research company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.20. The medical research company had revenue of $77.90 million for the quarter, compared to the consensus estimate of $73.97 million. Natera had a negative return on equity of 252.79% and a negative net margin of 42.45%. The firm's revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.49) earnings per share. View Natera's Earnings History.

When is Natera's next earnings date?

Natera is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Natera.

What price target have analysts set for NTRA?

5 analysts have issued 1 year price targets for Natera's shares. Their forecasts range from $32.00 to $49.00. On average, they expect Natera's share price to reach $42.40 in the next year. This suggests a possible upside of 14.2% from the stock's current price. View Analyst Price Targets for Natera.

What is the consensus analysts' recommendation for Natera?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natera.

What are Wall Street analysts saying about Natera stock?

Here are some recent quotes from research analysts about Natera stock:
  • 1. According to Zacks Investment Research, "Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. " (1/23/2020)
  • 2. Canaccord Genuity analysts commented, "We recently had the privilege of hosting Natera CEO Steve Chapman and CFO a well-attended fireside chat at the 39th in Boston. We continue to view NTRA as an undervalued cancer company trading at the multiple of an NIPT company. NTRA remains one of our favorite stocks and is one of our top picks for 2019. We reiterate our BUY rating and $38 PT. Signatera may be a game-changer in recurrence monitoring and MRD." (9/11/2019)

Has Natera been receiving favorable news coverage?

News coverage about NTRA stock has trended neutral recently, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Natera earned a daily sentiment score of 0.5 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Natera.

Are investors shorting Natera?

Natera saw a increase in short interest in January. As of January 31st, there was short interest totalling 3,990,000 shares, an increase of 9.6% from the January 15th total of 3,640,000 shares. Based on an average trading volume of 692,500 shares, the days-to-cover ratio is presently 5.8 days. Currently, 5.9% of the company's stock are sold short. View Natera's Current Options Chain.

Who are some of Natera's key competitors?

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

Who are Natera's key executives?

Natera's management team includes the folowing people:
  • Dr. Matthew Rabinowitz, Co-Founder & Exec. Chairman (Age 46)
  • Mr. Steve Chapman, CEO, Pres & Director (Age 40)
  • Mr. Michael Brophy, Chief Financial Officer (Age 39)
  • Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 46)
  • Mr. Robert A. Schueren, Chief Operating Officer (Age 57)

When did Natera IPO?

(NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Who are Natera's major shareholders?

Natera's stock is owned by many different of institutional and retail investors. Top institutional investors include Fred Alger Management LLC (4.79%), FMR LLC (4.76%), Jennison Associates LLC (3.27%), State Street Corp (3.21%), Bridger Management LLC (1.62%) and Credit Suisse AG (1.26%). Company insiders that own Natera stock include Claremont Creek Partners Fund, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman. View Institutional Ownership Trends for Natera.

Which major investors are selling Natera stock?

NTRA stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Driehaus Capital Management LLC, UBS Group AG, PNC Financial Services Group Inc., AXA, Bank of New York Mellon Corp, Rafferty Asset Management LLC and Perkins Capital Management Inc.. Company insiders that have sold Natera company stock in the last year include Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman. View Insider Buying and Selling for Natera.

Which major investors are buying Natera stock?

NTRA stock was acquired by a variety of institutional investors in the last quarter, including Bridger Management LLC, State Street Corp, Lord Abbett & CO. LLC, Renaissance Technologies LLC, Columbus Circle Investors, Parkman Healthcare Partners LLC, Madison Asset Management LLC and Credit Suisse AG. View Insider Buying and Selling for Natera.

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $37.13.

How big of a company is Natera?

Natera has a market capitalization of $2.88 billion and generates $257.65 million in revenue each year. The medical research company earns $-128,150,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Natera employs 975 workers across the globe.View Additional Information About Natera.

What is Natera's official website?

The official website for Natera is http://www.natera.com/.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected]


MarketBeat Community Rating for Natera (NASDAQ NTRA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  336 (Vote Outperform)
Underperform Votes:  305 (Vote Underperform)
Total Votes:  641
MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe NTRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel